Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 9010 results

  1. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  2. Oveporexton for treating type 1 narcolepsy [ID6622]

    In development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 18 May 2026.

    Technology appraisal guidance
    In consultation

  4. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development Reference number: GID-TA11019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Elamipretide for treating Barth syndrome in people of any age [ID6545]

    In development Reference number: GID-TA11719 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  17 September 2026

    Technology appraisal guidance
    In development

  8. Pegunigalsidase alfa every 4 weeks for treating Fabry disease [TSID12346]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Siponimod for treating multiple sclerosis in people 10 to 17 years [TSID12317]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

    Health technology evaluations
    In development

  11. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date:  12 August 2026

    NICE guideline
    In development

  12. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]

    In development Reference number: GID-TA11768 Expected publication date:  28 October 2026

    Technology appraisal guidance
    In development